CytomX Q2 2024 cash $137.2M; revenue $25.1M; CX-904 update expected by year-end

CytomX Therapeutics, Inc.

Cash, equivalents and investments $137.2M at June 30, 2024, down from $150.3M at March 31, 2024.
Total revenue $25.1M in Q2 2024, up from $24.7M in Q2 2023; R&D expense $25.2M incl. $5M milestone to AbbVie.
CX-904 (EGFRxCD3) Phase 1a enrollment continues in PDAC, NSCLC, HNSCC; program update expected by end of 2024.
CX-2051 (EpCAM ADC) Phase 1 dose escalation in third cohort; initial data expected in first half of 2025.
CX-801 (IFNα2b cytokine) first clinical site active; initial data expected in 2025; $10M Astellas milestones achieved YTD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.